A Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Trial to Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
Latest Information Update: 30 May 2025
At a glance
- Drugs CPX 101 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Guangzhou Chia Tai Innovative Pharmaceutical
Most Recent Events
- 28 Aug 2024 Status changed from not yet recruiting to recruiting.
- 08 Aug 2024 New trial record